Search results

Skip to results

Area of interest

Area of interest

Type

Type

Status

Status

Last updated

Last updated

Guidance programme

Advice programme

Showing 8341 to 8355 of 8941 results

  1. Pembrolizumab with lenvatinib for untreated advanced melanoma [ID3948]

    Discontinued Reference number: GID-TA10848

    Technology appraisal guidance
    Discontinued

  2. Pembrolizumab with lenvatinib for previously treated metastatic colorectal cancer [ID5112]

    Discontinued Reference number: GID-TA11020

    Technology appraisal guidance
    Discontinued

  3. Maribavir for cytomegalovirus infection after haematopoietic stem cell transplant [ID5075]

    Discontinued Reference number: GID-TA10958

    Technology appraisal guidance
    Discontinued

  4. Pembrolizumab with chemotherapy and surgery for treating resectable gastric or gastro-oesophageal junction cancer [ID2696]

    Discontinued Reference number: GID-TA10583

    Technology appraisal guidance
    Discontinued

  5. Ibrutinib for treating relapsed or refractory follicular lymphoma and marginal zone lymphoma [ID1251]

    Discontinued Reference number: GID-TA10525

    Technology appraisal guidance
    Discontinued

  6. Venetoclax with bortezomib and dexamethasone for treating relapsed or refractory multiple myeloma ID1565

    Discontinued Reference number: GID-TA10502

    Technology appraisal guidance
    Discontinued

  7. Atezolizumab with cabozantinib for treating metastatic non-small-cell lung cancer after platinum-based chemotherapy and 1 PD-L1 checkpoint inhibitor [ID6213]

    Discontinued Reference number: GID-TA11204

    Technology appraisal guidance
    Discontinued

  8. Magrolimab with azacitidine for untreated myelodysplastic syndromes [ID3978]

    Discontinued Reference number: GID-TA10861

    Technology appraisal guidance
    Discontinued

  9. Pembrolizumab with platinum chemotherapy, pemetrexed and lenvatinib for untreated advanced non-squamous non-small-cell lung cancer [ID3985]

    Discontinued Reference number: GID-TA10880

    Technology appraisal guidance
    Discontinued

  10. Belimumab with rituximab for treating systemic lupus erythematosus [ID3967]

    Discontinued Reference number: GID-TA10869

    Technology appraisal guidance
    Discontinued

  11. Palbociclib with trastuzumab and endocrine therapy for maintenance treatment of hormone-receptor positive, HER2-positive metastatic breast cancer [ID6251]

    In development Reference number: GID-TA11273 Expected publication date: TBC

    Technology appraisal guidance
    In development

  12. Cediranib with olaparib for treating recurrent platinum-resistant ovarian, fallopian tube or primary peritoneal cancer after 3 therapies [ID1639]

    In development Reference number: GID-TA10607 Expected publication date: TBC

    Technology appraisal guidance
    In development

  13. Pembrolizumab with lenvatinib for treating EGFR, ALK or ROS1-negative metastatic non-small-cell lung cancer after a PD-1 or PD-L1 inhibitor and platinum-based chemotherapy [ID5109]

    Discontinued Reference number: GID-TA11024

    Technology appraisal guidance
    Discontinued

  14. Durvalumab with concurrent chemoradiation for treating unresectable locally advanced non-small-cell lung cancer [ID3906]

    Discontinued Reference number: GID-TA10783

    Technology appraisal guidance
    Discontinued

  15. Sabatolimab with azacitidine for untreated high-risk myelodysplastic syndromes [ID3996]

    Discontinued Reference number: GID-TA10897

    Technology appraisal guidance
    Discontinued